NoticiasCon ayuda de IA

Apollomics Board Expands With Appointment Of Dr. Ya-Chi (Claudia) Huang; Strengthens Audit And Corporate Governance Committees

Apollomics appoints Dr. Ya-Chi Huang to its Board and key committees following the resignation of Po-Jen Hsueh.

Simantini Singh Deo
Por Simantini Singh Deo
Redactor/a Senior
18 nov 20252 min de lectura
Apollomics Board Expands With Appointment Of Dr. Ya-Chi (Claudia) Huang; Strengthens Audit And Corporate Governance Committees
Reportaje con ayuda de IA
Reviewed by Simantini Singh Deo, Redactor/a Senior

Apollomics Inc., a California-based late-stage clinical biopharmaceutical company, announced updates to its board of directors and committee composition. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. His resignation was not due to any disagreement with the Company. At a Board meeting on the same day, Dr. Ya-Chi (Claudia) Huang was appointed to fill the vacancy left by Mr. Hsueh. Dr. Huang will also assume his roles on the Company’s Audit Committee and Nominating and Corporate Governance Committee.


Following these changes and prior director appointments, the Apollomics Board now consists of seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Among them, Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang serve as independent directors. 


Dr. Ya-Chi (Claudia) Huang brings significant experience in biotechnology investment, corporate governance, and research and development within Taiwan’s biopharmaceutical sector. She currently serves as Assistant Vice President at Maxpro Ventures, leading domestic and international investments and overseeing post-investment operations. Dr. Huang is also a director at AngenMed Therapeutics.


Previously, Dr. Huang was an Investment Manager at Diamond Biofund (6901.TW), completing multiple investments and managing post-investment activities, including participation in Diamond Biofund’s 2023 IPO on the Taiwan Stock Exchange. She also worked as Deputy Manager in the Research Department at Fubon Securities Investment Services, evaluating over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, contributing to substantial growth in Fubon’s investment banking profits.


Dr. Huang’s scientific background includes research roles at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize at the 12th TienTe Lee Biomedical Award. She holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.

Simantini Singh Deo
Written by
Simantini Singh Deo
Redactor/a Senior

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Cargando la conversación…

Más de Pharma News

Todos los artículos →